Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy.
Su-Ping GuoChen ChenZhi-Fan ZengQiao-Xuan WangWu JiangYuan-Hong GaoHui ChangPublished in: Cancer management and research (2021)
Serum apolipoprotein A-I was found to correlate negatively with the RC response to NACRT. It could serve as a biomarker for guiding individualized treatment and a potential target for improving sensitivity to chemoradiation.